ClinicalTrials.gg
TerminatedNCT03955471MOONSTONEUpdated Sep 10, 2022Results posted

Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer

A Phase 2 interventional study of Niraparib and Dostarlimab in Ovarian Neoplasms, sponsored by Tesaro, Inc.. Terminated at 27 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-10.

Sponsored by Tesaro, Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study will not resume based on the results of a planned interim analysis that showed futility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Ovarian Neoplasms by GlaxoSmithKline — 5 open to participants now, 7 under way, 5 of them phase 3. Ovarian Neoplasms · GlaxoSmithKline.

Enrollment
19th of 30
41 · median 77
Started
2019
the only one that year
Phase 2
15 of 31
1 open now
Registered
24th of 31
by date

Among the 31 studies in Ovarian Neoplasms by GlaxoSmithKline, this one is the 19th largest by enrollment of the 30 interventional ones that give a count, is the only one that started in 2019, is one of 15 in phase 2, and was the 24th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 31 studies in Ovarian Neoplasms by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Ovarian Neoplasms by GlaxoSmithKline, or all of them as a file.
02

Study summary

This is an open-label, single-arm Phase 2 study to evaluate the efficacy and safety of combination of niraparib and dostarlimab (TSR-042) in participants with advanced, relapsed, high-grade ovarian, fallopian tube, endometrioid, clear cell ovarian or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease and who have also been previously treated with bevacizumab.

03

Conditions studied

  • Ovarian Neoplasms

Browse trials for

Keywords

  • Open-label
  • Single-arm
  • Efficacy and Safety
  • Platinum-resistant ovarian cancer
  • Niraparib
  • dostarlimab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be female >=18 years of age, able to understand the study procedures, and subsequently agreed to participate in the study by providing written .
  • Participants must have recurrent high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer.
  • Participants must be considered resistant to the last administered platinum therapy.
  • Participants must have completed at least 1 but no more than 3 for advanced or ovarian cancer.
  • Participants must have been previously treated with platinum-based regimen, taxane agent(s), and bevacizumab.
  • Participant has according to v.1.1.
  • Participant has an (ECOG) performance status of 0 or 1.
  • Participant has adequate organ function.
  • Females with have a serum pregnancy test that is negative 72 prior first dose and are not breastfeeding. Participant must also agree to abstain from activities that could result in pregnancy from enrollment through 180 days after the last dose of study treatment.
  • Participant must provide formalin fixed paraffin embedded (FFPE) tumor tissue block(s) with sufficient tumor content (as confirmed by the Sponsor's designated central laboratory) during screening to enable BRCA testing and testing. The use of slides created from paraffin-embedded tissue as opposed to FFPE blocks must be approved by the Sponsor.
  • Participant must agree to complete health-related quality of life (HRQoL) questionnaires throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Participant who experienced disease progression within 3 months (12 weeks or 84 days) of platinum therapy.
  • Participants with a known deleterious or suspected BRCA 1 or 2 mutation.
  • Participant has received prior therapy with an , anti-PD-L1 or anti-PD-L2 agent.
  • Participant has received prior therapy with a PARP-1/PARP-2 inhibitor.
  • Participant has a known to dostarlimab (TSR-042), Niraparib, their components, or their .
  • Participant has a known history of myelodysplastic syndrome or acute myeloid leukemia.
  • Participant has not recovered from prior chemotherapy induced adverse events.
  • Participant has a known diagnosis of immunodeficiency or is receiving systemic therapy exceeding an equivalent of prednisone 10 mg daily or any other form of therapy within 7 days prior to the first dose of study treatment.
  • Participant is currently participating in a treatment study or has participated in a study of an agent within 4 weeks of the first dose of treatment.
  • Participant has received prior systemic anticancer therapy including cytotoxic chemotherapy, hormonal therapy given with the intention to treat ovarian cancer, or biological therapy within 3 weeks of the first dose of study treatment.
  • Participant has received within 14 days of planned start of study therapy
  • Participant has symptomatic uncontrolled brain or . (If investigator feels participant symptoms are not symptomatic, participants can undergo a scan to confirm for eligibility).
  • Participant had major surgery with 4 weeks of starting the first dose of the study treatment or participant has not recovered from any effects of any major surgery.
  • Participant has a known additional that progressed or required active treatment within the last 2 years.
  • Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active controlled infection.
  • Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study.
  • Participant has known active (hepatitis B surface antigen reactive) or (hepatitis C virus ribonucleic acid, qualitative).
  • Participant with a known history of (HIV) are allowed if they meet all of the following criteria:

    1. Cluster of differentiation 4 >=350/microliter (μL) and viral load \<400 copies/milliliter (mL)
    2. No history of acquired immunodeficiency syndrome-defining opportunistic infections within 12 months prior to enrollment
    3. No history of HIV-associated malignancy for the past 5 years
    4. Concurrent antiretroviral therapy as per the most current National Institutes of Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV started >4 weeks prior to study enrollment
  • Participant is immunocompromised. Participants with splenectomy are allowed.
  • Participant has an ongoing bowel obstruction or has other conditions that would lead to impaired absorption of oral niraparib.
  • Participant has active disease that has required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Niraparib+Dostarlimab (TSR-042)

    Participants with body weight ≥77 kilogram (kg) and platelet count ≥150,000/microliter (μL) at baseline were administered Niraparib 300 milligram (mg) once daily (QD) and participants with body weight \<77 kg or platelet count \<150,000/μL at baseline were administered Niraparib 200 mg QD. Niraparib was administered continuously until Progressive disease (PD) or toxicity. Dostarlimab (TSR-042) was administered as an intravenous (IV) infusion of 500 mg once every three weeks (Q3W) from Cycle 1 Day 1 through Cycle 4. Beginning at Cycle 5, Dostarlimab (TSR-042) was administered via an IV infusion of 1000 mg on Day 1 of each 6-week cycle until PD or toxicity, up to 27 months.

    Drug: Niraparib · Drug: Dostarlimab

Interventions

  • Niraparib is a potent, orally active poly (adenosine diphosphate-ribose) polymerase (PARP)-1 and PARP2 inhibitor being developed as a treatment for participants with tumors that harbor defects in the homologous recombination deoxyribonucleic acid (DNA) repair pathway or that are driven by PARP-mediated transcription factors.

    Also known as: ZEJULA

  • TSR-042 is a humanized monoclonal antibody that binds with high affinity to programmed cell death-1 (PD-1) resulting in inhibition of binding to programmed cell-death receptor ligands 1 and 2 (PD-L1 and PD-L2).

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) in Participants With Platinum-resistant Ovarian Cancer (PROC)

    ORR is defined as the percentage of participants who have achieved confirmed complete response (CR) or partial response (PR), as determined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria based on Investigator assessment and computed tomography (CT) scans were commonly used for tumor imaging.

    Time frame: Up to approximately 22 months

  2. ORR in Participants With PROC Who Have Programmed Cell Death-ligand 1 (PD-L 1) Positive Status

    ORR is defined as the percentage of participants who have achieved confirmed CR or PR, as determined by RECIST v1.1 criteria based on Investigator assessment and CT scans were commonly used for tumor imaging. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with combined positive score (vCPS) \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

    Time frame: Up to approximately 22 months

Secondary outcomes

  1. Duration of Response (DOR) in Participants With PROC

    DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment.

    Time frame: Up to approximately 22 months

  2. DOR in Participants With PROC Who Have PD-L 1 Positive Status

    DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

    Time frame: Up to approximately 22 months

  3. Progression-free Survival (PFS) in Participants With PROC

    PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment.

    Time frame: Up to approximately 22 months

  4. PFS in Participants With PROC Who Have PD-L 1 Positive Status

    PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

    Time frame: Up to approximately 22 months

  5. Overall Survival (OS) in Participants With PROC

    OS is defined as the time from the date of the first dose of study treatment to the date of death by any cause.

    Time frame: Up to approximately 22 months

  6. OS in Participants With PROC Who Have PD-L 1 Positive Status

    OS is defined as the time from the date of the first dose of study treatment to the date of death by any cause. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

    Time frame: Up to approximately 22 months

  7. Disease Control Rate (DCR) in Participants With PROC

    DCR is defined as the percentage of participants who have achieved best overall response (BOR) of CR, PR, or stable disease (SD) per RECIST v.1.1 based on the investigator's assessment.

    Time frame: Up to approximately 22 months

  8. DCR in Participants With PROC Who Have PD-L 1 Positive Status

    DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on the investigator's assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

    Time frame: Up to approximately 22 months

  9. ORR in Participants With PROC Based on Independent Review Committee (IRC) Assessment

    ORR is defined as the percentage of participants who have achieved confirmed CR or PR per RECIST v1.1 based on the independent review committee assessment.

    Time frame: Up to approximately 22 months

  10. ORR in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment

    ORR is defined as the percentage of participants who have achieved confirmed CR or PR per RECIST v1.1 based on the independent review committee assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

    Time frame: Up to approximately 22 months

  11. DOR in Participants With PROC Based on IRC Assessment

    DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee assessment.

    Time frame: Up to approximately 22 months

  12. DOR in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment

    DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

    Time frame: Up to approximately 22 months

  13. PFS in Participants With PROC Based on IRC Assessment

    PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee Assessment.

    Time frame: Up to approximately 22 months

  14. PFS in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment

    PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on IRC Assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

    Time frame: Up to approximately 22 months

  15. DCR in Participants With PROC Based on IRC Assessment

    DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on IRC Assessment.

    Time frame: Up to approximately 22 months

  16. DCR in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment

    DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on Independent Review Committee Assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

    Time frame: Up to approximately 22 months

  17. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-emergent Adverse Events (TEAEs) and Adverse Event of Special Interest (AESI)

    An AE is any untoward medical occurrence in a patient administered with a medicinal product and that does which may or may not have a causal relationship with this treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. TEAEs are any event that occurred between first dose of study drug up to 22 months, which were absent before treatment or that had worsened relative to pretreatment state. AESI were any AE (serious or non-serious) that is of scientific and medical concern specific to the study treatment, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was done.

    Time frame: Up to approximately 27 months

  18. Number of Participants With Grade Shift From Baseline in Hematology

    Blood samples were collected for the analysis of hematology parameters and each parameter was graded according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.3. Grade 0: Normal, Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent measurement prior to the first administration of study treatment. Data has been presented for the number of participants with hematology grade shifts from baseline grade to grade 3 and 4 for each parameter.

    Time frame: Up to approximately 27 months

  19. Number of Participants With Grade Shift From Baseline in Plasma Chemistry

    Blood samples were collected and the clinical chemistry parameters assessed were Albumin (Alb), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), alkaline phosphatase (ALP), sodium, total bilirubin (TB), creatinine, glucose, magnesium and potassium. The Grade shift post baseline data of each parameter from Grade 0 through Grade 4 was based on the CTCAE version 4.03, grading scale, as per intensity, namely Grade 0: Normal, Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent measurement prior to the first administration of study treatment. Data has been presented for the number of participants with plasma chemistry grade shifts from baseline grade to grade 3 and 4 for each parameter.

    Time frame: Up to approximately 27 months

  20. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Baseline was defined as the most recent measurement prior to the first administration of study treatment. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The minimum (min) and maximum (max) change from baseline values have been reported.

    Time frame: Up to approximately 27 months

  21. Change From Baseline in Pulse Rate

    Baseline was defined as the most recent measurement prior to the first administration of study treatment. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The minimum (min) and maximum (max) change from baseline values have been reported.

    Time frame: Up to approximately 27 months

  22. Change From Baseline in Temperature

    Baseline was defined as the most recent measurement prior to the first administration of study treatment. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The minimum (min) and maximum (max) change from baseline values have been reported.

    Time frame: Up to approximately 27 months

  23. Change From Baseline in Prothrombin International Normalized Ratio

    Blood samples were collected to evaluate Prothrombin International Normalized Ratio (INR). Baseline was defined as the most recent measurement prior to the first administration of study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and up to approximately 27 months

  24. Change in Baseline in Activated Partial Thromboplastin Time

    Blood samples were planned to be collected to evaluate activated partial thromboplastin time (APTT). Baseline was defined as the most recent measurement prior to the first administration of study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and up to approximately 27 months

  25. Change From Baseline in Thyrotropin

    Blood samples were collected to evaluate thyrotropin at indicated time points. Baseline was defined as the most recent measurement prior to the first administration of study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

    Time frame: Baseline and up to approximately 27 months

07

Results

Posted Sep 10, 2022

Participant flow

From October 2019 until September 2020, 72 participants were screened and 41 participants were enrolled (31 screen failures)

Participant flow — Overall Study
MilestoneNiraparib+Dostarlimab (TSR-042)
Started41
Completed1
Not completed40
Withdrew: Death22
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject6
Withdrew: Sponsor decision to terminate study11

Outcome measures

PrimaryObjective Response Rate (ORR) in Participants With Platinum-resistant Ovarian Cancer (PROC)

ORR is defined as the percentage of participants who have achieved confirmed complete response (CR) or partial response (PR), as determined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) criteria based on Investigator assessment and computed tomography (CT) scans were commonly used for tumor imaging.

Time frame:
Up to approximately 22 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) in Participants With Platinum-resistant Ovarian Cancer (PROC)
Percentage of ParticipantsNiraparib+Dostarlimab (TSR-042)
Objective Response Rate (ORR) in Participants With Platinum-resistant Ovarian Cancer (PROC)7.3 (1.5 to 19.9)
PrimaryORR in Participants With PROC Who Have Programmed Cell Death-ligand 1 (PD-L 1) Positive Status

ORR is defined as the percentage of participants who have achieved confirmed CR or PR, as determined by RECIST v1.1 criteria based on Investigator assessment and CT scans were commonly used for tumor imaging. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with combined positive score (vCPS) \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

Time frame:
Up to approximately 22 months
Reported as:
Number · Percentage of Participants
ORR in Participants With PROC Who Have Programmed Cell Death-ligand 1 (PD-L 1) Positive Status
Percentage of ParticipantsNiraparib+Dostarlimab (TSR-042)
ORR in Participants With PROC Who Have Programmed Cell Death-ligand 1 (PD-L 1) Positive Status7.7 (0.2 to 36)
SecondaryDuration of Response (DOR) in Participants With PROC

DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment.

Time frame:
Up to approximately 22 months
Reported as:
Median · Months
Duration of Response (DOR) in Participants With PROC
MonthsNiraparib+Dostarlimab (TSR-042)
Duration of Response (DOR) in Participants With PROC3.8 (3 to 9.2)
SecondaryDOR in Participants With PROC Who Have PD-L 1 Positive Status

DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

Time frame:
Up to approximately 22 months
Reported as:
Median · Months
DOR in Participants With PROC Who Have PD-L 1 Positive Status
MonthsNiraparib+Dostarlimab (TSR-042)
DOR in Participants With PROC Who Have PD-L 1 Positive StatusNA (3.8 to NA)
SecondaryProgression-free Survival (PFS) in Participants With PROC

PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment.

Time frame:
Up to approximately 22 months
Reported as:
Median · Months
Progression-free Survival (PFS) in Participants With PROC
MonthsNiraparib+Dostarlimab (TSR-042)
Progression-free Survival (PFS) in Participants With PROC2.1 (1.97 to 2.23)
SecondaryPFS in Participants With PROC Who Have PD-L 1 Positive Status

PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Investigator assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

Time frame:
Up to approximately 22 months
Reported as:
Median · Months
PFS in Participants With PROC Who Have PD-L 1 Positive Status
MonthsNiraparib+Dostarlimab (TSR-042)
PFS in Participants With PROC Who Have PD-L 1 Positive Status2.22 (1.64 to NA)
SecondaryOverall Survival (OS) in Participants With PROC

OS is defined as the time from the date of the first dose of study treatment to the date of death by any cause.

Time frame:
Up to approximately 22 months
Reported as:
Median · Months
Overall Survival (OS) in Participants With PROC
MonthsNiraparib+Dostarlimab (TSR-042)
Overall Survival (OS) in Participants With PROC10.61 (7.26 to 13.44)
SecondaryOS in Participants With PROC Who Have PD-L 1 Positive Status

OS is defined as the time from the date of the first dose of study treatment to the date of death by any cause. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

Time frame:
Up to approximately 22 months
Reported as:
Median · Months
OS in Participants With PROC Who Have PD-L 1 Positive Status
MonthsNiraparib+Dostarlimab (TSR-042)
OS in Participants With PROC Who Have PD-L 1 Positive StatusNA (7.26 to NA)
SecondaryDisease Control Rate (DCR) in Participants With PROC

DCR is defined as the percentage of participants who have achieved best overall response (BOR) of CR, PR, or stable disease (SD) per RECIST v.1.1 based on the investigator's assessment.

Time frame:
Up to approximately 22 months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) in Participants With PROC
Percentage of ParticipantsNiraparib+Dostarlimab (TSR-042)
Disease Control Rate (DCR) in Participants With PROC29.3 (16.1 to 45.5)
SecondaryDCR in Participants With PROC Who Have PD-L 1 Positive Status

DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on the investigator's assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

Time frame:
Up to approximately 22 months
Reported as:
Number · Percentage of Participants
DCR in Participants With PROC Who Have PD-L 1 Positive Status
Percentage of ParticipantsNiraparib+Dostarlimab (TSR-042)
DCR in Participants With PROC Who Have PD-L 1 Positive Status38.5 (13.9 to 68.4)
SecondaryORR in Participants With PROC Based on Independent Review Committee (IRC) Assessment

ORR is defined as the percentage of participants who have achieved confirmed CR or PR per RECIST v1.1 based on the independent review committee assessment.

Time frame:
Up to approximately 22 months

No measurements were reported for this outcome.

SecondaryORR in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment

ORR is defined as the percentage of participants who have achieved confirmed CR or PR per RECIST v1.1 based on the independent review committee assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

Time frame:
Up to approximately 22 months

No measurements were reported for this outcome.

SecondaryDOR in Participants With PROC Based on IRC Assessment

DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee assessment.

Time frame:
Up to approximately 22 months

No measurements were reported for this outcome.

SecondaryDOR in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment

DOR is defined as the time from first documentation of response (CR or PR) until the time of first documentation of disease progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

Time frame:
Up to approximately 22 months

No measurements were reported for this outcome.

SecondaryPFS in Participants With PROC Based on IRC Assessment

PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on Independent Review Committee Assessment.

Time frame:
Up to approximately 22 months

No measurements were reported for this outcome.

SecondaryPFS in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment

PFS is defined as the time from the date of the first dose of study treatment to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v.1.1 based on IRC Assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with a vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

Time frame:
Up to approximately 22 months

No measurements were reported for this outcome.

SecondaryDCR in Participants With PROC Based on IRC Assessment

DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on IRC Assessment.

Time frame:
Up to approximately 22 months

No measurements were reported for this outcome.

SecondaryDCR in Participants With PROC Who Have PD-L 1 Positive Status Based on IRC Assessment

DCR is defined as the percentage of participants who have achieved BOR of CR, PR, or SD per RECIST v.1.1 based on Independent Review Committee Assessment. PD-L1 is a ligand that binds to PD-L1 protein on tumor infiltrating T cells and renders the T cells inactive. Any PD-L1 positive tissue sample with vCPS \>=5% was used as specified cut-point for the assessment of PD-L1 positive patient subset with PROC. vCPS was defined as the percentage of tumor cells and immune cells staining positive within the total tumor area.

Time frame:
Up to approximately 22 months

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-emergent Adverse Events (TEAEs) and Adverse Event of Special Interest (AESI)

An AE is any untoward medical occurrence in a patient administered with a medicinal product and that does which may or may not have a causal relationship with this treatment. A SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. TEAEs are any event that occurred between first dose of study drug up to 22 months, which were absent before treatment or that had worsened relative to pretreatment state. AESI were any AE (serious or non-serious) that is of scientific and medical concern specific to the study treatment, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was done.

Time frame:
Up to approximately 27 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-emergent Adverse Events (TEAEs) and Adverse Event of Special Interest (AESI)
ParticipantsNiraparib+Dostarlimab (TSR-042)
AEs41
SAEs23
TEAE41
AESIs2
SecondaryNumber of Participants With Grade Shift From Baseline in Hematology

Blood samples were collected for the analysis of hematology parameters and each parameter was graded according to National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 4.3. Grade 0: Normal, Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent measurement prior to the first administration of study treatment. Data has been presented for the number of participants with hematology grade shifts from baseline grade to grade 3 and 4 for each parameter.

Time frame:
Up to approximately 27 months
Reported as:
Count of participants · Participants
Number of Participants With Grade Shift From Baseline in Hematology
ParticipantsNiraparib+Dostarlimab (TSR-042)
Hemoglobin, Grade 0 to Grade 33
Hemoglobin, Grade 1 to Grade 35
Hemoglobin, Grade 2 to Grade 31
Hemoglobin, Grade 3 to Grade 30
Hemoglobin, Grade 4 to Grade 30
Hemoglobin, Grade 0 to Grade 40
Hemoglobin, Grade 1 to Grade 40
Hemoglobin, Grade 2 to Grade 40
Hemoglobin, Grade 3 to Grade 40
Hemoglobin, Grade 4 to Grade 40
Leukocytes, Grade 0 to Grade 30
Leukocytes, Grade 1 to Grade 30
Leukocytes, Grade 2 to Grade 30
Leukocytes, Grade 3 to Grade 30
Leukocytes, Grade 4 to Grade 30
Leukocytes, Grade 0 to Grade 40
Leukocytes, Grade 1 to Grade 40
Leukocytes, Grade 2 to Grade 40
Leukocytes, Grade 3 to Grade 40
Leukocytes, Grade 4 to Grade 40
Lymphocytes, Grade 0 to Grade 35
Lymphocytes, Grade 1 to Grade 33
Lymphocytes, Grade 2 to Grade 33
Lymphocytes, Grade 3 to Grade 30
Lymphocytes, Grade 4 to Grade 30
Lymphocytes, Grade 0 to Grade 41
Lymphocytes, Grade 1 to Grade 40
Lymphocytes, Grade 2 to Grade 40
Lymphocytes, Grade 3 to Grade 40
Lymphocytes, Grade 4 to Grade 40
Neutrophil Count, Grade 0 to Grade 31
Neutrophil Count, Grade 1 to Grade 30
Neutrophil Count, Grade 2 to Grade 30
Neutrophil Count, Grade 3 to Grade 30
Neutrophil Count, Grade 4 to Grade 30
Neutrophil Count, Grade 0 to Grade 41
Neutrophil Count, Grade 1 to Grade 40
Neutrophil Count, Grade 2 to Grade 40
Neutrophil Count, Grade 3 to Grade 40
Neutrophil Count, Grade 4 to Grade 40
Platelets, Grade 0 to Grade 34
Platelets, Grade 1 to Grade 31
Platelets, Grade 2 to Grade 30
Platelets, Grade 3 to Grade 30
Platelets, Grade 4 to Grade 30
Platelets, Grade 0 to Grade 44
Platelets, Grade 1 to Grade 40
Platelets, Grade 2 to Grade 40
Platelets, Grade 3 to Grade 40
Platelets, Grade 4 to Grade 40
SecondaryNumber of Participants With Grade Shift From Baseline in Plasma Chemistry

Blood samples were collected and the clinical chemistry parameters assessed were Albumin (Alb), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), alkaline phosphatase (ALP), sodium, total bilirubin (TB), creatinine, glucose, magnesium and potassium. The Grade shift post baseline data of each parameter from Grade 0 through Grade 4 was based on the CTCAE version 4.03, grading scale, as per intensity, namely Grade 0: Normal, Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. Baseline was defined as the most recent measurement prior to the first administration of study treatment. Data has been presented for the number of participants with plasma chemistry grade shifts from baseline grade to grade 3 and 4 for each parameter.

Time frame:
Up to approximately 27 months
Reported as:
Count of participants · Participants
Number of Participants With Grade Shift From Baseline in Plasma Chemistry
ParticipantsNiraparib+Dostarlimab (TSR-042)
ALT, Grade 0 to Grade 33
ALT, Grade 1 to Grade 30
ALT, Grade 2 to Grade 30
ALT, Grade 3 to Grade 30
ALT, Grade 4 to Grade 30
ALT, Grade 0 to Grade 41
ALT, Grade 1 to Grade 40
ALT, Grade 2 to Grade 40
ALT, Grade 3 to Grade 40
ALT, Grade 4 to Grade 40
Alb, Grade 0 to Grade 31
Alb, Grade 1 to Grade 30
Alb, Grade 2 to Grade 30
Alb, Grade 3 to Grade 30
Alb, Grade 4 to Grade 30
Alb, Grade 0 to Grade 40
Alb, Grade 1 to Grade 40
Alb, Grade 2 to Grade 40
Alb, Grade 3 to Grade 40
Alb, Grade 4 to Grade 40
ALP, Grade 0 to Grade 33
ALP, Grade 1 to Grade 31
ALP, Grade 2 to Grade 31
ALP, Grade 3 to Grade 30
ALP, Grade 4 to Grade 30
ALP, Grade 0 to Grade 40
ALP, Grade 1 to Grade 41
ALP, Grade 2 to Grade 40
ALP, Grade 3 to Grade 40
ALP, Grade 4 to Grade 40
Amylase, Grade 0 to Grade 30
Amylase, Grade 1 to Grade 30
Amylase, Grade 2 to Grade 30
Amylase, Grade 3 to Grade 30
Amylase, Grade 4 to Grade 30
Amylase, Grade 0 to Grade 40
Amylase, Grade 1 to Grade 40
Amylase, Grade 2 to Grade 40
Amylase, Grade 3 to Grade 40
Amylase, Grade 4 to Grade 40
AST, Grade 0 to Grade 34
AST, Grade 1 to Grade 31
AST, Grade 2 to Grade 30
AST, Grade 3 to Grade 30
AST, Grade 4 to Grade 30
AST, Grade 0 to Grade 40
AST, Grade 1 to Grade 40
AST, Grade 2 to Grade 40
AST, Grade 3 to Grade 40
AST, Grade 4 to Grade 40
TB, Grade 0 to Grade 31
TB, Grade 1 to Grade 30
TB, Grade 2 to Grade 30
TB, Grade 3 to Grade 30
TB, Grade 4 to Grade 30
TB, Grade 0 to Grade 41
TB, Grade 1 to Grade 40
TB, Grade 2 to Grade 40
TB, Grade 3 to Grade 40
TB, Grade 4 to Grade 40
Creatinine, Grade 0 to Grade 31
Creatinine, Grade 1 to Grade 30
Creatinine, Grade 2 to Grade 30
Creatinine, Grade 3 to Grade 30
Creatinine, Grade 4 to Grade 30
Creatinine, Grade 0 to Grade 40
Creatinine, Grade 1 to Grade 40
Creatinine, Grade 2 to Grade 40
Creatinine, Grade 3 to Grade 40
Creatinine, Grade 4 to Grade 40
Glucose high, Grade 0 to Grade 30
Glucose high, Grade 1 to Grade 33
Glucose high, Grade 2 to Grade 30
Glucose high, Grade 3 to Grade 31
Glucose high, Grade 4 to Grade 30
Glucose high, Grade 0 to Grade 40
Glucose high, Grade 1 to Grade 40
Glucose high, Grade 2 to Grade 40
Glucose high, Grade 3 to Grade 40
Glucose high, Grade 4 to Grade 40
Glucose low, Grade 0 to Grade 30
Glucose low, Grade 1 to Grade 30
Glucose low, Grade 2 to Grade 30
Glucose low, Grade 3 to Grade 30
Glucose low, Grade 4 to Grade 30
Glucose low, Grade 0 to Grade 40
Glucose low, Grade 1 to Grade 40
Glucose low, Grade 2 to Grade 40
Glucose low, Grade 3 to Grade 40
Glucose low, Grade 4 to Grade 40
Magnesium high, Grade 0 to Grade 31
Magnesium high, Grade 1 to Grade 30
Magnesium high, Grade 2 to Grade 30
Magnesium high, Grade 3 to Grade 30
Magnesium high, Grade 4 to Grade 30
Magnesium high, Grade 0 to Grade 40
Magnesium high, Grade 1 to Grade 40
Magnesium high, Grade 2 to Grade 40
Magnesium high, Grade 3 to Grade 40
Magnesium high, Grade 4 to Grade 40
Magnesium low, Grade 0 to Grade 30
Magnesium low, Grade 1 to Grade 30
Magnesium low, Grade 2 to Grade 30
Magnesium low, Grade 3 to Grade 31
Magnesium low, Grade 4 to Grade 30
Magnesium low, Grade 0 to Grade 40
Magnesium low, Grade 1 to Grade 40
Magnesium low, Grade 2 to Grade 40
Magnesium low, Grade 3 to Grade 40
Magnesium low, Grade 4 to Grade 40
Potassium high, Grade 0 to Grade 30
Potassium high, Grade 1 to Grade 30
Potassium high, Grade 2 to Grade 30
Potassium high, Grade 3 to Grade 30
Potassium high, Grade 4 to Grade 30
Potassium high, Grade 0 to Grade 40
Potassium high, Grade 1 to Grade 40
Potassium high, Grade 2 to Grade 40
Potassium high, Grade 3 to Grade 40
Potassium high, Grade 4 to Grade 40
Potassium low, Grade 0 to Grade 33
Potassium low, Grade 1 to Grade 31
Potassium low, Grade 2 to Grade 30
Potassium low, Grade 3 to Grade 30
Potassium low, Grade 4 to Grade 30
Potassium low, Grade 0 to Grade 40
Potassium low, Grade 1 to Grade 40
Potassium low, Grade 2 to Grade 40
Potassium low, Grade 3 to Grade 40
Potassium low, Grade 4 to Grade 40
Sodium high, Grade 0 to Grade 30
Sodium high, Grade 1 to Grade 30
Sodium high, Grade 2 to Grade 30
Sodium high, Grade 3 to Grade 30
Sodium high, Grade 4 to Grade 30
Sodium high, Grade 0 to Grade 40
Sodium high, Grade 1 to Grade 40
Sodium high, Grade 2 to Grade 40
Sodium high, Grade 3 to Grade 40
Sodium high, Grade 4 to Grade 40
Sodium low, Grade 0 to Grade 34
Sodium low, Grade 1 to Grade 37
Sodium low, Grade 2 to Grade 30
Sodium low, Grade 3 to Grade 30
Sodium low, Grade 4 to Grade 30
Sodium low, Grade 0 to Grade 40
Sodium low, Grade 1 to Grade 40
Sodium low, Grade 2 to Grade 40
Sodium low, Grade 3 to Grade 40
Sodium low, Grade 4 to Grade 40
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Baseline was defined as the most recent measurement prior to the first administration of study treatment. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The minimum (min) and maximum (max) change from baseline values have been reported.

Time frame:
Up to approximately 27 months
Reported as:
Mean · Millimeters of mercury
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercuryNiraparib+Dostarlimab (TSR-042)
DBP, max change post baseline10.6 ± 10.07
DBP, min change post baseline-5.8 ± 11.87
SBP, max change post baseline16.5 ± 23.01
SBP, min change post baseline-12.5 ± 24.61
SecondaryChange From Baseline in Pulse Rate

Baseline was defined as the most recent measurement prior to the first administration of study treatment. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The minimum (min) and maximum (max) change from baseline values have been reported.

Time frame:
Up to approximately 27 months
Reported as:
Mean · Beats per minute
Change From Baseline in Pulse Rate
Beats per minuteNiraparib+Dostarlimab (TSR-042)
max change post baseline20.5 ± 14.71
min change post baseline1 ± 13.77
SecondaryChange From Baseline in Temperature

Baseline was defined as the most recent measurement prior to the first administration of study treatment. The change from baseline was calculated by subtracting the baseline values from the individual post-randomization values. The minimum (min) and maximum (max) change from baseline values have been reported.

Time frame:
Up to approximately 27 months
Reported as:
Mean · Degrees Celsius
Change From Baseline in Temperature
Degrees CelsiusNiraparib+Dostarlimab (TSR-042)
max change post baseline0.31 ± 0.421
min change post baseline-0.35 ± 0.422
SecondaryChange From Baseline in Prothrombin International Normalized Ratio

Blood samples were collected to evaluate Prothrombin International Normalized Ratio (INR). Baseline was defined as the most recent measurement prior to the first administration of study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and up to approximately 27 months
Reported as:
Mean · Ratio
Change From Baseline in Prothrombin International Normalized Ratio
RatioNiraparib+Dostarlimab (TSR-042)
Day 20.2
Day 410.3
Day 520.7
SecondaryChange in Baseline in Activated Partial Thromboplastin Time

Blood samples were planned to be collected to evaluate activated partial thromboplastin time (APTT). Baseline was defined as the most recent measurement prior to the first administration of study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and up to approximately 27 months
Reported as:
Mean · Second
Change in Baseline in Activated Partial Thromboplastin Time
SecondNiraparib+Dostarlimab (TSR-042)
Day 21
Day 4116.9
SecondaryChange From Baseline in Thyrotropin

Blood samples were collected to evaluate thyrotropin at indicated time points. Baseline was defined as the most recent measurement prior to the first administration of study treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value.

Time frame:
Baseline and up to approximately 27 months
Reported as:
Mean · Milliunits per liter (mU/L)
Change From Baseline in Thyrotropin
Milliunits per liter (mU/L)Niraparib+Dostarlimab (TSR-042)
Cycle 5 Day 18.074 ± 19.737
Cycle 7 Day 112.79 ± 23.240
Cycle 9 Day 12.596
Cycle 11 Day 12.517

Adverse events

Collected over All cause mortality, non-SAEs and SAEs were collected from Day 1 up to approximately 27 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Niraparib+Dostarlimab (TSR-042)22/41 (53.7%)23/41 (56.1%)41/41 (100%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventNiraparib+Dostarlimab (TSR-042)
ThrombocytopeniaBlood and lymphatic system disorders3/41
Small intestinal obstructionGastrointestinal disorders3/41
DyspnoeaRespiratory, thoracic and mediastinal disorders3/41
AnaemiaBlood and lymphatic system disorders2/41
Intestinal obstructionGastrointestinal disorders2/41
VomitingGastrointestinal disorders2/41
Blood bilirubin increasedInvestigations2/41
Pleural effusionRespiratory, thoracic and mediastinal disorders2/41
TachycardiaCardiac disorders1/41
Abdominal painGastrointestinal disorders1/41
Most frequent other events
Showing 10 of 45
Most frequent other events
EventNiraparib+Dostarlimab (TSR-042)
NauseaGastrointestinal disorders24/41
VomitingGastrointestinal disorders19/41
AnaemiaBlood and lymphatic system disorders18/41
FatigueGeneral disorders18/41
Abdominal painGastrointestinal disorders15/41
ConstipationGastrointestinal disorders15/41
DiarrhoeaGastrointestinal disorders11/41
Platelet count decreasedInvestigations11/41
Blood creatinine increasedInvestigations10/41
Blood alkaline phosphatase increasedInvestigations10/41

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Niraparib+Dostarlimab (TSR-042)
Mean62.9 ± 10.59
Sex: Female, Male
Sex: Female, Male(Participants)Niraparib+Dostarlimab (TSR-042)
Female41
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Niraparib+Dostarlimab (TSR-042)
American Indian or Alaska Native1
Asian2
Black or African American3
Unknown3
White32
08

Study locations

27 sites
  • GSK Investigational Site
    Scottsdale, Arizona 85258, United States
  • GSK Investigational Site
    Duarte, California 91010, United States
  • GSK Investigational Site
    Newport Beach, California 92663, United States
  • GSK Investigational Site
    Orange, California 92868, United States
  • GSK Investigational Site
    Solvang, California 93463, United States
  • GSK Investigational Site
    Deerfield Beach, Florida 33442, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Orlando, Florida 32804, United States
  • GSK Investigational Site
    Tampa, Florida 33612, United States
  • GSK Investigational Site
    Iowa City, Iowa 52242-1009, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Burlington, Massachusetts 01805, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
  • GSK Investigational Site
    Jackson, Mississippi 39216, United States
  • GSK Investigational Site
    New York, New York 10022, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Cleveland, Ohio 44106, United States
  • GSK Investigational Site
    Cleveland, Ohio 44124, United States
  • GSK Investigational Site
    Eugene, Oregon 97401, United States
  • GSK Investigational Site
    Providence, Rhode Island 02905, United States
  • GSK Investigational Site
    Chattanooga, Tennessee 37403, United States
  • GSK Investigational Site
    Germantown, Tennessee 38138, United States
  • GSK Investigational Site
    Austin, Texas 78731, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22903, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Aug 2021, 22 months.

Results were first posted in Sep 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2019
First posted
May 20, 2019
StartActual
Oct 3, 2019
Primary completionActual
Aug 18, 2021
CompletionActual
Jan 12, 2022
Results first posted
Sep 10, 2022
Last update
Sep 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03955471
Lead sponsor
Tesaro, Inc.
Responsible party
Sponsor
First posted
May 20, 2019
Start date
Oct 3, 2019
Primary completion
Aug 18, 2021
Completion
Jan 12, 2022
Results posted
Sep 10, 2022
Last update
Sep 10, 2022

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion